Hypertension Management in Stroke Prevention

Hypertension is the single most important modifiable risk factor for stroke, contributing to approximately 50% of ischemic strokes and the majority of hemorrhagic strokes. Even modest blood pressure reductions translate into significant stroke risk reduction — a 10 mmHg decrease in systolic BP reduces stroke risk by approximately 30-40%.

BP Targets: The Evidence

Multiple trials have examined intensive versus standard BP control. Recent evidence increasingly supports lower targets, particularly for hemorrhagic stroke prevention.

SPS3 Blood Pressure (2013)

The SPS3 Blood Pressure trial randomized 3,020 patients with recent lacunar stroke to a lower SBP target (<130 mmHg) versus higher target (130-149 mmHg):

• Recurrent stroke: 2.25%/year vs 2.77%/year — HR 0.81, p=0.08 (trend toward benefit, not significant)
• Intracerebral hemorrhage: Significantly reduced — HR 0.37, p=0.03 (63% reduction)
• Achieved BP: 127 mmHg vs 138 mmHg

Although the primary endpoint did not reach significance, the direction of effect and the significant ICH reduction support targeting SBP <130 mmHg in lacunar stroke patients.

SPRINT (2015)

The SPRINT trial tested intensive BP control (<120 mmHg) versus standard (<140 mmHg) in 9,361 high-risk adults without diabetes or prior stroke:

• Primary endpoint (CV events): 1.77%/year vs 2.40%/year — HR 0.73, p<0.001
• All-cause mortality: HR 0.75, p=0.006
• Stroke: Similar rates (not significantly reduced — few events)
• Adverse events: Increased hypotension, syncope, AKI, electrolyte abnormalities with intensive control

Note: SPRINT excluded patients with prior stroke or diabetes. The intensive target showed CV benefit but the stroke signal was limited by few events.

ESPRIT (2024) and Stroke Analysis (2025)

The ESPRIT trial randomized 11,255 high-risk Chinese patients (39% with diabetes, 27% with prior stroke) to intensive (<120 mmHg) versus standard (<140 mmHg) BP targets over 3.4 years:

• Primary MACE: 3.2% vs 3.6% — HR 0.88, p=0.03
• CV death: HR 0.61, p<0.001
• All-cause mortality: HR 0.79, p=0.03
• Achieved BP: 119 mmHg vs 135 mmHg

Stroke subanalysis (JACC 2025): Among 565 stroke events, intensive treatment showed:

• All stroke: 4.7% vs 5.4% — HR 0.86, p=0.08 (trend)
• Ischemic stroke: HR 0.93, p=0.42 (NS)
• Hemorrhagic stroke: 0.4% vs 0.8% — HR 0.51, p=0.009 (49% reduction)
• Landmark analysis: Stroke benefit emerged after 1 year — HR 0.75, p=0.01 for follow-up >1 year

ESPRIT importantly included patients with diabetes and prior stroke (excluded from SPRINT), demonstrating that intensive BP control benefits these populations.

BPROAD (2025)

The BPROAD trial randomized 12,821 patients with type 2 diabetes and elevated CV risk to intensive (<120 mmHg) versus standard (<140 mmHg) targets:

• Primary endpoint (MACE): 1.65 vs 2.09 events/100 person-years — HR 0.79, p<0.001
• Stroke: HR 0.79 (21% reduction)
• CV death: HR 0.76
• Adverse events: More symptomatic hypotension (0.1% vs <0.1%) and hyperkalemia (2.8% vs 2.0%)

BPROAD provides definitive evidence that intensive BP control benefits diabetic patients — addressing a gap left by the earlier ACCORD trial which was underpowered.

PAST-BP (2016)

The PAST-BP trial tested intensive (<130 mmHg) versus standard (<140 mmHg) targets in 529 stroke/TIA patients in UK primary care:

• SBP reduction: 16.1 mmHg vs 12.8 mmHg — difference 2.9 mmHg, p=0.03
• Not powered for clinical outcomes; supports feasibility of lower targets in primary care

First-Line Antihypertensive Agents

For stroke secondary prevention, guidelines recommend initiating or resuming antihypertensive therapy after the first 24-72 hours when the patient is neurologically stable. Four drug classes are considered first-line:

Beta-blockers are not first-line for hypertension alone but are indicated for patients with concurrent heart failure, CAD, or atrial fibrillation.

Combination Therapy

Most stroke patients require ≥2 antihypertensive agents to reach target. Effective combinations include:

• ACE-i or ARB + CCB — Excellent combination; synergistic; CCB reduces ACE-i–associated edema
• ACE-i or ARB + thiazide — Effective; monitor potassium
• CCB + thiazide — Good for patients intolerant of RAAS blockers

Avoid: ACE-i + ARB combination (increased adverse events without additional benefit)

The Triple Pill Approach

The traditional "start low, go slow" approach with monotherapy and stepwise uptitration often results in therapeutic inertia and delayed BP control. An alternative strategy — starting with low-dose combination therapy — achieves target BP faster with comparable tolerability.

TRIUMPH Trial (2018)

The TRIUMPH trial randomized 700 patients with mild-to-moderate hypertension to a low-dose triple pill versus usual care:

Triple Pill composition:

• Telmisartan 20 mg (ARB)
• Amlodipine 2.5 mg (CCB)
• Chlorthalidone 12.5 mg (thiazide-type diuretic)

Results at 6 months:

• BP at target (<140/90): 70% (triple pill) vs 55% (usual care) — p<0.001
• Mean BP reduction: 9/5 mmHg greater with triple pill
• Achieved BP: 125/76 mmHg vs 134/81 mmHg
• Adverse events: Similar between groups; no increase in serious events
• Time to control: Faster — 68% at target by 6 weeks vs 44% with usual care

TRIDENT Trial (2025) — Triple Pill After ICH

The TRIDENT trial randomized patients with prior primary ICH (SBP 130-160 mmHg) to a low-dose triple pill versus placebo, on top of background care:

Triple Pill composition:

• Telmisartan 20 mg
• Amlodipine 2.5 mg
• Indapamide 1.25 mg

Key Results:

• Recurrent stroke: HR 0.61, p=0.017 — 39% reduction (NNT 27)
• Recurrent ICH: HR 0.40, p=0.003 — 60% reduction
• MACE: HR 0.67, p=0.02
• Safety signal: More ≥30% eGFR reductions (7.7% vs 4.3%) — monitor renal function

TRIDENT provides landmark evidence that intensive BP lowering with a triple pill dramatically reduces recurrent stroke after ICH — the first trial to show this magnitude of benefit in secondary ICH prevention.

Practical Approach

Trial Comparison Table

* Statistically significant. NS = not significant. DM = diabetes mellitus. ICH = intracerebral hemorrhage.

References

1. Benavente OR, et al. Blood-pressure targets in patients with recent lacunar stroke (SPS3). Lancet. 2013;382:507-515.
2. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116.
3. Mant J, et al. Different systolic blood pressure targets for people with history of stroke or TIA (PAST-BP). BMJ. 2016;352:i708.
4. Webster R, et al. Fixed low-dose triple combination antihypertensive medication vs usual care (TRIUMPH). JAMA. 2018;320:566-579.
5. Liu J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk (ESPRIT). Lancet. 2024;404:245-255.
6. Liu J, et al. Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial. J Am Coll Cardiol. 2025 (in press).
7. Bi Y, et al. Intensive blood-pressure control in patients with type 2 diabetes (BPROAD). N Engl J Med. 2025 (in press).
8. TRIDENT Investigators. Low-dose triple single-pill combination for secondary prevention after ICH. 2025.
9. Kleindorfer DO, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and TIA. Stroke. 2021;52:e364-e467.
10. Whelton PK, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71:e13-e115.